Entries by Sally Wagner Partin

08 09 '26

When AI Changes The Deal: Seven AI-related Considerations for Life Sciences M&A Dealmakers

/in , , , /by

Sally Wagner Partin, Sharon R. Flanagan, and Torrey Cope consider how AI is reshaping drug development, particularly at the stages of target and compound identification, and set out the implications of those changes for valuation, diligence, risk, milestone design, and timing in life sciences transactions.

27 01 '26

Delaware Supreme Court Makes Earnouts Less Risky For Buyers
Earnout Decision Partially Reversed Because Buyer Did Not Have to Pursue an Alternative Regulatory Pathway

/in , , , , , , /by

Earnouts are a common feature of life sciences deals, and a 2024 Chancery Court decision had increased the financial risk for buyers agreeing to an earnout.  However, the Delaware Supreme […]